"Baxalta is working with bankers on the acquisition of a U.S.-based hematology-oncology specialist valued at about $2 billion, said the people, who asked not to be identified because the information is private.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.